BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 15365073)

  • 1. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
    Thirion P; Michiels S; Pignon JP; Buyse M; Braud AC; Carlson RW; O'Connell M; Sargent P; Piedbois P;
    J Clin Oncol; 2004 Sep; 22(18):3766-75. PubMed ID: 15365073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
    Grem JL
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-8-S18-18. PubMed ID: 9420016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
    Nogué M; Salud A; Batiste-Alentorn E; Saigí E; Losa F; Cirera L; Méndez M; Campos JM; Galan A; Escudero P; Arcusa A; Manzano H; de Mendizábal EV; de Olaguer JP; Boleda M; Guasch I; Vicente P
    Eur J Cancer; 2005 Oct; 41(15):2241-9. PubMed ID: 16214045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.
    Thirion P; Piedbois P; Buyse M; O'Dwyer PJ; Cunningham D; Man A; Greco FA; Colucci G; Köhne CH; Di Constanzo F; Piga A; Palmeri S; Dufour P; Cassano A; Pajkos G; Pensel RA; Aykan NF; Marsh J; Seymour MT;
    Br J Cancer; 2001 Mar; 84(5):611-20. PubMed ID: 11237380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Leucovorin and 5-FU for advanced gastrointestinal cancer].
    Sasaki T; Maeda Y; Kobayashi T
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):440-6. PubMed ID: 10097740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomodulation of 5-fluorouracil with antifolates.
    Bertino JR
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
    Makower D; Wadler S
    Semin Oncol; 1999 Dec; 26(6):663-71. PubMed ID: 10606259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    Saltz LB; Niedzwiecki D; Hollis D; Goldberg RM; Hantel A; Thomas JP; Fields AL; Mayer RJ
    J Clin Oncol; 2007 Aug; 25(23):3456-61. PubMed ID: 17687149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
    Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
    J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The biochemical modulation of 5-fluorouracil by leucovorin].
    Borner M; Brunner K
    Schweiz Med Wochenschr; 1991 Aug; 121(33):1149-56. PubMed ID: 1925442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line chemotherapy with low-dose leucovorin plus 5-fluorouracil (LV/5-FU) for elderly patients with metastatic colorectal cancer.
    Yoshimatsu K; Yokomizo H; Fujimoto T; Umehara A; Otani T; Matsumoto A; Osawa G; Shiozawa S; Katsube T; Naritaka Y; Ogawa K
    Anticancer Res; 2007; 27(3B):1641-4. PubMed ID: 17595789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
    Yeoh C; Chau I; Cunningham D; Norman AR; Hill M; Ross PJ
    Clin Colorectal Cancer; 2003 Aug; 3(2):102-7. PubMed ID: 12952566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of 5-FU-based bolus chemotherapy on survival in patients with advanced colorectal cancer.
    Van Halteren HK; Roumen RM; Coebergh JW; Croiset van Uchelen FA; Keuning JJ; Vreugdenhil G
    Anticancer Res; 1999; 19(4C):3447-9. PubMed ID: 10629633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer.
    Fields AL; Keller A; Schwartzberg L; Bernard S; Kardinal C; Cohen A; Schulz J; Eisenberg P; Forster J; Wissel P
    J Clin Oncol; 2009 Apr; 27(12):1941-7. PubMed ID: 19273708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
    J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
    Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
    J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.